UNASSIGNED: The most common site for @entity5 to spread is bone. At post-mortem, bony @entity3 have been found in 70% of @entity1 dying from @entity0 . Due to the prevalence of @entity5 , bone @entity3 and the associated management represents a huge burden on @entity9462 resources. In @entity1 with @entity3 , around 56% of these involve the lower limb long bones. Due to the huge forces placed upon long bones during weight bearing, there is a high risk of @entity174 through areas of @entity3 . It is reported that 23% of pathological @entity174 occur in the femoral subtrochanteric region. This area is subjected to forces up to four times the body weight, resulting in poor union rate for these @entity174 , and significant morbidity associated with difficulty in mobilising, and in @entity1 nursing. As @entity5 treatments improve, the life expectancy in this subgroup of @entity1 is likely to increase. Therefore medium-to-long-term management of these @entity174 , beyond the palliative, will become essential. We aim to evaluate the current management for metastatic @entity2096 , with particular focus on the prophylactic augmentation of diseased femorii using intramedullary nails.

The current status of prophylactic femoral intramedullary nailing for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast and prostate cancer'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity9462 :: ('MESH:C538336', 'Disease') :: ['NHS'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases'] @entity2096 :: ('MESH:D020428', 'Disease') :: ['malignant femoral disease']
@entity5 :: (MESH:D009369,Disease) :: ['metastatic cancer']
